Background: HIV-associated diarrhea remains a signifi cant concern with limited treatment options. Objective: To determine the optimal dose, effi cacy, and safety of crofelemer for noninfectious diarrhea. Methods: This randomized, double-blind, phase 3 trial used a 2-stage design. Both stages included 2-week screening, 4-week placebo-controlled treatment, and 20-week placebo-free (open-label) extension phases. In stage I, 196 HIV-seropositive patients with chronic diarrhea were randomized to crofelemer 125 mg, 250 mg, or 500 mg or placebo twice daily. Using a prospective analysis, the 125-mg twice-daily dose was selected for stage II. In stage II, 180 new patients were randomized to crofelemer 125 mg twice daily or placebo for 4 weeks. Primary effi cacy analysis was the percentage of patients (stages I/II combined) who achieved clinical response (defi ned as ≤2 watery stools/week during ≥2 of 4 weeks). During the placebo-free extension phase, response (≤2 watery stools) was assessed weekly. Results: Signifi cantly more patients receiving crofelemer 125 mg achieved clinical response versus placebo (17.6% vs 8.0%; one-sided, P = .01). Crofelemer 125 mg resulted in a greater change from baseline in number of daily watery bowel movements (P = .04) and daily stool consistency score (P = .02) versus placebo. During the placebo-free extension phase, percentages of weekly responders ranged from 40% to 56% at weeks 11 to 24. Crofelemer was minimally absorbed, well tolerated, did not negatively impact clinical immune parameters, and had a safety profi le comparable to placebo. Conclusions: In HIV-seropositive patients taking stable antiretroviral therapy, crofelemer provided signifi cant improvement in diarrhea with a favorable safety profi le.
have decreased in the era of combination antiretroviral therapy (cART), there has been a simultaneous increase in noninfectious diarrhea, with an estimated prevalence of up to 28% in community-based studies for patients receiving cART. 1, 5, 7 Overall, although the tolerance and toxicity profi le of current cART regimens has generally improved, intolerance or toxicity remains a major cause of ART discontinuation or switching in patients with HIV. 8, 9 Many patients taking cART experience adverse effects, including diarrhea, that not only have a substantial negative impact on overall health, but also increase health care resource utilization and negatively impact work productivity. 10 A clinical trial review indicated that up to 19% of cART-treated individuals experienced drug-related diarrhea that was at least moderate in intensity. 11 In a 12-year analysis of fi rst-line antiretroviral discontinuation, gastrointestinal symptoms were the most common adverse events (AEs) associated with treatment discontinuation. 12 In a survey of cART-treated patients (n = 953), diarrhea (63.0%) ranked second only to fatigue (70.7%) as the most common medication adverse effect reported during the previous month. 10 Addressing AEs by switching from one ART to another is a viable alternative for some individuals, but it comes with a potential risk of psychologic and physical disease burden and reduced quality of life. 13 Because diarrhea may result in nonadherence or treatment modifi cations in cART, [14] [15] [16] [17] [18] this phenomenon represents a substantial challenge globally in HIV management, with implications for cART efficacy and drug resistance. 19 However, chronic diarrhea in patients with HIV is often under-recognized and under-treated. 20, 21 This under-recognition is likely impacted by multiple factors, including the focus of health care providers on other high-burden symptoms, reluctance by patients to discuss the impact of their diarrheal symptoms, or lack of a clear algorithm or strategy to manage the condition. Furthermore, the lack of randomized, controlled data with antidiarrheal medications for noninfectious forms of HIV-associated diarrhea has hindered evidence-based management strategies. 5, 22 Diarrhea in patients with HIV is commonly a leaky-fl ux or secretory diarrhea, which is caused by high rates of chloride ion (Cl − ) and subsequent sodium ion and high-volume water fl ow into the gastrointestinal lumen. 23, 24 Chloride ion and subsequent fl uid secretion by gastrointestinal epithelial cells in secretory diarrhea is predominantly controlled by 2 ion channels: the cyclic adenosine monophosphate (cAMP)-stimulated cystic fi brosis transmembrane conductance regulator (CFTR) Cl − channel and the calcium-activated Cl − channel (CaCC). 23 Crofelemer, a dual inhibitor of the CFTR Cl − channel and CaCC, [25] [26] [27] is a fi rst-in-class, minimally absorbed gastrointestinal drug derived from a botanical source-the stem bark latex of the Croton lechleri tree, which is used traditionally as an antidiarrheal remedy by indigenous Amazonian tribes. 25 Crofelemer inhibition of the CFTR Cl − channel and CaCC channel reduces Cl − secretion and the accompanying high-volume water secretion into the gastrointestinal lumen, producing an antidiarrheal effect. [25] [26] [27] The Antidiarrhea Therapy in HIV Disease−Emerging Treatment Concepts (ADVENT) trial was designed to determine the optimal crofelemer dose and evaluate crofelemer for the treatment of noninfectious diarrhea in HIVseropositive individuals.
METHODS

Setting and Participants
HIV-seropositive individuals ≥18 years of age from the United States and Puerto Rico taking a stable cART regimen for ≥4 weeks who had a history of diarrhea (persistently loose stools despite regular antidiarrheal medication use or ≥1 watery bowel movement per day without regular antidiarrheal use) for ≥1 month were eligible for enrollment. Key exclusion criteria included pregnancy or breastfeeding, a CD4+ cell count <100 cells/mm 3 , presence of fecal pathogens requiring antibiotic treatment within 14 days of screening, or a positive gastrointestinal biopsy, gastrointestinal culture, or stool test in the previous 4 months for any of the following: Clostridium diffi cile toxin, Campylobacter spp, Cyclospora spp, Cryptosporidium spp, Cytomegalovirus spp, Entamoeba spp, Giardia spp, Isospora spp, Microsporidium spp, Mycobacterium spp, Salmonella spp, Shigella spp, or Yersinia spp. All patients provided written informed consent.
Study Design
This phase 3, randomized, double-blind, placebo-controlled, multicenter trial used a 2-stage (dose selection and dose assessment) design
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( Figure 1 ) to allow selection of the optimal dose for fi nal effi cacy and safety determinations within a single trial. Both stage I and stage II consisted of a placebo-only screening phase of 10 (+4) days; a 31-day, double-blind, placebo-controlled phase; and a 20-week, placebo-free (open-label) extension phase. Each stage had a unique set of patients (ie, participation in either stage I or stage II) with identical assessments conducted. Throughout the study, patients recorded diarrhea symptoms, adherence to study medication and ART, and use of antidiarrheal or prohibited medications through an interactive voice response system (IVRS). Use of antidiarrheal medication or opioids (beginning 2 weeks prior to screening) was prohibited during the placebo-controlled phase; antidiarrheal medications were allowed during the placebo-free (open-label) phase. Following randomization into the placebocontrolled phase, patients took study medication for a 3-day run-in period before entering a 4-week effi cacy assessment period. Patient-rated effi cacy assessments were entered into the IVRS daily beginning on day 4. Safety information, including AEs (excluding those prospectively defi ned per modifi ed Centers for Disease Control and Prevention guidelines as AIDS-defi ning events), concomitant medications, clinical laboratory tests, and stool samples were collected at 2 and 4 weeks following randomization (stool samples at week 4 only).
In stage I, patients with ≥1 watery stool per day on ≥5 of the last 7 days of the screening phase and urgency on ≥1 of the last 7 days were randomized 1:1:1:1 to crofelemer 125 mg, 250 mg, or 500 mg or placebo twice daily. Upon completion of the placebo-controlled phase, stage I patients entered a 20-week placebo-free (open-label) extension phase, in which patients receiving placebo were re-randomized 1:1:1 to 1 of the 3 crofelemer doses.
In a prospectively planned analysis to determine the dose for stage II, an independent interim analysis committee (IAC), consisting of 4 independent physicians and 1 consulting statistician, reviewed stage I results. The IAC assessed the primary effi cacy endpoint (see below) in the stage I intent-to-treat (ITT) population and AE and serious AE rates. In the absence of substantial safety issues, the dose selected for stage II was the dose that resulted in effi cacy (based on the primary outcome) ≥2.0% greater than the other doses; if 2 or 3 treatment groups had effi cacy scores within 2.0% of each other and no safety issues arose, the lowest dose would be selected. If safety issues were present, the IAC was to evaluate their signifi cance and determine treatment arms accordingly. In stage II, new patients were randomized 1:1 to receive the selected dose of crofelemer or placebo. The protocol was approved by the institutional review board or independent ethics committee for each study site.
The study was conducted in accordance with US law and the International Conference on Harmonisation Good Clinical Practice guidelines.
Randomization and Masking
All patients took placebo during screening. At randomization, a randomization number and treatment group for each patient was obtained via the IVRS system. Patients, investigators, and other study site and sponsor personnel were blinded to the randomization schema throughout the study, and crofelemer and placebo tablets were identical in appearance and labeling. The study blind was maintained during the interim analysis, which was conducted by an independent statistician. Following the IAC determination, only personnel with direct contact with the study medication for preparation and shipment were unblinded.
Outcomes and Follow-Up
The primary effi cacy endpoint was the percentage of patients in the ITT population (stages I and II combined) achieving clinical response, defi ned as ≤2 watery stools per week for at least 2 of 4 weeks during the placebo-controlled phase. Secondary effi cacy endpoints included the number of watery stools per day, daily stool consistency score (1 = very hard, 2 = hard, 3 = formed, 4 = loose, 5 = watery), daily abdominal pain or discomfort score (0 = none, 1 = mild, 2 = moderate, 3 = severe), days per week patients experienced urgency, days per week patients experienced fecal incontinence, and number of stools per day. During the extension phase, clinical response (≤2 watery stools) was assessed weekly, based on patient-rated diary results entered into the IVRS daily. Stool samples were obtained at screening and at the end of the placebo-controlled phase. In addition, during each 4-week visit of the extension phase, a stool sample was required if a patient reported watery or loose bowel movements.
Safety variables included AEs, clinical laboratory parameters, vital signs, electrocardiogram, worsening and/or clinically signifi cant exacerbation of diarrhea, and HIV clinical parameters (eg, HIV-1 viral load [lower limit of quantifi cation, 400 copies/mL] and CD4+ cell count). Plasma samples were collected at baseline and days 29 + 3 (pre dose), 57 ± 4, 113 ± 4, and 169 ± 4 (pre dose) for analysis of crofelemer concentrations by high performance liquid chromatography with fl uorescence detection. The lower limit of quantifi cation for crofelemer was 50 ng/mL.
Statistical Analysis
The primary and secondary effi cacy endpoints compared the optimal selected dose of crofelemer in the study to placebo across study stages using the ITT population. The ITT population comprised all randomized patients receiving ≥1 administration of study drug. The safety population comprised the ITT population with ≥1 postbaseline visit. Safety data were summarized across stages. Sample-size calculations were based on an estimated response rate of 1 or more of the crofelemer dose groups exceeding placebo by 20%. With 71% to >91% power to detect a treatment difference at a one-sided alpha of 0.025, 125 subjects needed to be randomized to the 2 primary treatment groups (optimal crofelemer dose group and placebo group). The primary effi cacy analysis used the technique described by Posch et al, 28 based on the original work of Bauer and Kieser, 29 which controlled the type 1 error rate for the 2-stage design at a one-sided alpha of 0.025. P values from the 2 stages were combined by the inverse normal weighting combination function. A closed testing procedure was implemented to test the null hypothesis that the selected dose was no worse than placebo versus the one-sided alternative hypothesis that the selected dose was better. This statistical analysis was agreed to by the US Food and Drug Administration (FDA). See the eAppendix for additional information on the adaptive design and determination of sample size. (The online version of this article [doi: 10.1310/hct1406-261] contains the eAppendix and is available to authorized users.)
For secondary endpoints, change from baseline in continuous outcomes was analyzed using analysis of covariance (ANCOVA) with treatment effect and baseline value as covariates. The issue of
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multiplicity of secondary effi cacy measurements was managed by statistical testing in a hierarchical fashion. Signifi cance tests for secondary effi cacy measurements were conducted until a nonsignifi cant 2-sided P value (>.05) was found; all subsequent tests were considered exploratory.
Patients with <5 days of effi cacy data in a given week were classifi ed as nonresponders for that week. Patients who discontinued prematurely or used antidiarrheal medication or opioid pain medication for >3 days during the 4-week effi cacy assessment period were also classifi ed as nonresponders. For the primary endpoint, responsiveness was assessed by a Wilcoxon rank-sum test to compare the change from baseline in each of the diarrheal symptoms measured in the study, in clinical responders versus nonresponders, regardless of treatment. P values are 2-sided unless otherwise indicated. Statistical analyses were conducted using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
Role of the Funding Source
The study protocol was designed by Napo Pharmaceuticals, Inc. and the academic authors in collaboration with the FDA. Salix Pharmaceuticals, Inc. assumed all regulatory, operational, compliance, and reporting obligations early in the conduct of the trial. Data were collected by the principal investigators (listed in the eAppendix) and were monitored by the contract research organization Kendle until study obligations were transferred to Salix. An editorial consultant was paid by Salix to assist in revising and editing the manuscript. All authors vouch for the completeness and veracity of the data and analyses. Dr. MacArthur had full access to all the data and had fi nal responsibility for the decision to submit for publication.
RESULTS
Patient Disposition
A total of 376 patients were randomized to treatment (Figure 2A and 2B ). Of these, 374 patients comprised the ITT population and 363 patients comprised the safety population. Two individuals who were randomized but failed to initiate therapy were excluded. Most patients (>85%) in each treatment group completed the placebo-controlled phase. 
A Demographics and Baseline Characteristics
In the combined analysis (stage I and II), demographic and baseline characteristics were comparable across treatment groups in each trial phase ( Table 1) . At baseline, nearly all patients (>97%) in the ITT population reported current ART use and most (≥64%) were receiving protease inhibitors. During the placebo-controlled phase, the most frequently used ART included tenofovir/emtricitabine, ritonavir (100-200 mg/d combined with other protease inhibitors), lopinavir/ ritonavir, and efavirenz/ tenofovir/emtricitabine ( Table 1) . A majority of patients (62.6%) had a history of antidiarrheal medication use, with loperamide hydrochloride being the most common agent (44.9% of patients).
Selection of Optimal Dose
Based on the stage I interim analysis, 125 mg twice daily was selected as the optimal dose. Findings showed the highest percentage of responders in the crofelemer 125 mg twice daily group (20.0%). There were no apparent safety issues.
Primary and Secon dary Effi cacy Endpoints
A signifi cantly larger percentage of patients in the crofelemer 125 mg twice daily group achieved clinical response during 4 weeks versus placebo in a combined analysis of stage I and stage II (P = .01, one-sided; Table 2 ). Compared with placebo, the crofelemer 125 mg twice daily group also showed signifi cant improvement from baseline in number of daily watery bowel movements (P = .04) and daily stool consistency score (P = .02; Table 2 ). There were no signifi cant differences between crofelemer 125 mg twice daily and placebo for other secondary endpoints.
A responsiveness analysis was conducted for the primary endpoint by analyzing clinical response with other daily assessments as secondary endpoints ( Table 3) . Regardless of treatment group, the primary endpoint consistently appeared to align with other daily assessments collected, and clinical responders had signifi cantly greater improvements in daily symptom severity scores than nonresponders during each of the 4 weeks of treatment (P < .022 for all).
Additional Analyses
Subgroup analyses of the percentage of responders in the placebo-controlled phase (stages I and II combined) revealed pronounced treatment differences favoring crofelemer 125 mg twice daily versus placebo for patients with more severe (>2 daily watery stools) baseline diarrhea (12.0% vs 2.4%; P = .03), diarrhea for >2 years (18.7% vs 7.6%; P = .03), and baseline stool consistency scores >4 (17.1% vs 8.4%; P = .05). Patients using antidiarrheal medication prior to study participation were more likely to respond to 125 mg twice daily crofelemer than to placebo (18.1% vs 3.5%; P = .002), particularly patients who had previously used multiple (≥2) antidiarrheal medications (27.6% vs 0%; P = .001).
Placebo-Free (Open-Label) Extension
The effect of crofelemer 125 mg twice daily appeared to be maintained during the 5-month extension (Figure 3) , with a trend toward higher percentages of weekly responders in each treatment group (continuing crofelemer patients and placebo crossover patients) with increasing duration of treatment, stabilizing at 40% to 56% of patients from week 11 through week 24. Antidiarrheal medication, the most common of which was loperamide hydrochloride (n = 8), was used by only 5.9% (13/220) of patients treated with crofelemer 125 mg twice daily during this phase.
Safety
Minimal systemic crofelemer absorption was observed, with >96% of patients having plasma concentrations below the limit of quantitation. The safety profi le for crofelemer was comparable to placebo in each dose group; there was no apparent dose-response relationship for AEs ( Table 4) . One death (diffuse large B-cell lymphoma) occurred in the placebo group and one death (cardiac arrest) occurred in the crofelemer 125 mg twice daily group. Neither death was considered by the investigator to be drug related.
During the placebo-controlled phase, 2 patients (<0.8%) receiving crofelemer 125 mg twice daily experienced serious AEs (Escherichia coli sepsis and pneumonia). Neither serious AE was considered by investigators to be drug related. Four patients receiving placebo (2.9%) experienced 5 serious Note: Data are given as n (%). AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; PYE = person-years of exposure.
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AEs (diffuse large B-cell lymphoma, phlebitis, and pneumonia in 1 patient each; acute pancreatitis and alcohol withdrawal syndrome both in 1 patient). During the extension phase, 13 patients (3.9%) receiving crofelemer experienced serious AEs; none were considered drug related, and all (excluding the cardiac arrest death) resolved. Shifts from baseline in HIV clinical parameters were minimal throughout the study. During the placebo-controlled phase, only 3.1% of all crofelemer-treated patients versus 2.9% of placebo-treated patients experienced an increase from baseline in HIV viral load from <400 to ≥400 copies/mL. Only 3.5% of crofelemer-treated versus 5.8% of placebotreated patients experienced shifts from baseline in CD4+ cell count from >500 cells/mm 3 to ≤500 cells/mm 3 . Results were similar during the extension phase. Only 5.3% of all crofelemer-treated patients experienced an increase from baseline in HIV viral load from <400 to ≥400 copies/mL and 5.9% experienced shifts from baseline in CD4+ cell count from >500 cells/mm 3 to ≤500 cells/mm 3 .
DISCUSSION
The current study is the fi rst phase 3 trial of crofelemer in HIV-seropositive individuals with chronic diarrhea. Given the multifactorial etiology of HIV-associated diarrhea and the baseline characteristics of the study population, comprising individuals experiencing chronic diarrhea for, in many, ≥5.5 years and with a mean of 2.6 to 3.0 watery stools per day (>18 watery stools per week), the primary endpoint criterion of clinical response can be considered a stringent criterion for improvement. Despite this challenge, signifi cantly more patients treated with crofelemer 125 mg twice daily met the criterion compared with placebo. The improvements with crofelemer for clinical response and for number of daily watery stools and stool consistency were statistically signifi cant and clinically meaningful. The primary endpoint was supported by responsiveness analyses conducted to validate that it accurately detected clinically meaningful changes in diarrheal symptom severity. In addition, effi cacy appeared to be maintained during the 5-month extension, with the percentage of weekly responders tending to increase or stabilize at approximately 50%. Results were consistent with previous studies of crofelemer in different patient populations (eg, cholera and travelers' diarrhea), 30, 31 indicating that the gut-targeted binding of crofelemer to CFTR and CaCC may have utility for other pathogenic states that involve dysregulation of intestinal chloride channels.
More pronounced crofelemer treatment effects were observed in patients with diarrhea of greater severity (≥2 watery stools per day) or duration (>2 years) or who had used multiple (≥2) antidiarrheal medications prior to the study. Collectively, these results suggest a therapeutic benefi t in patients with persistent diarrhea despite antidiarrheal use.
Crofelemer was well tolerated, with minimal system absorption, had a safety profi le consistent for the HIV-seropositive population studied, and had no negative impact on clinical immune parameters (HIV viral load and CD4+ cell counts). In addition, the incidence of constipation was low, with none of the cases considered to be serious AEs. Safety fi ndings were comparable to placebo and consistent with a phase 2 study of crofelemer in HIV-seropositive patients. 32 The study has several limitations. The placebocontrolled phase of the study was short and precluded formal analyses of continued improvements that occurred after week 4 of the study. In addition, the defi nition of clinical responder for the primary endpoint, although internally validated within the current study, will need to be independently assessed as a valid construct. This conservative defi nition of improvement may have accounted for the rather low rates of clinical responders in both treatment groups.
CONCLUSION
The successful treatment of diarrhea in HIVseropositive individuals has a number of important potential benefi ts, including improvements in adherence to cART, nutritional status, weight control, and quality of life. 2, [33] [34] [35] However, few treatment options are available specifi cally to treat HIV-associated diarrhea. 5 Despite their current use and effectiveness in some patients, 36, 37 agents that affect gastrointestinal motility have not been systematically investigated in patients with HIV. 22 In addition, these agents can be associated with treatment-limiting AEs, including drug interactions with ART regimens (loperamide), 38 abuse liability (difenoxin, tincture of opium), 22, 37 and gastrointestinal disturbances (somatostatin and analogues). 37 An advantage of crofelemer is the low rate of AEs (comparable to placebo), consistent with its minimal systemic absorption. In late 2012, crofelemer was approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on ART.
In conclusion, diarrhea contributes to worsening quality of life and complicates medical care, and effective treatment in HIV-seropositive individuals is a signifi cant unmet clinical need. Results of the current study demonstrate that in HIV-seropositive patients receiving ART, crofelemer 125 mg twice daily provides signifi cant improvement in noninfectious diarrhea with a safety profi le comparable to placebo.
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